SC Asks Uttarakhand Govt To Finalize Decision On Suspension Of 14 Patanjali Products In Two Weeks

New Delhi: The Supreme Court on Tuesday directed the Uttarakhand government to decide on the suspension of 14 products by yoga guru Ramdev’s Patanjali Ayurved, reported Live Law.

A bench of Justices Hima Kohli and Sandeep Mehta directed the Bharatiya Janata Party government in the state to decide on the matter within two weeks.

On April 29, the Uttarakhand State Licensing Authority for Ayurvedic and Unani Services told the court that the licences were suspended as Patanjali Ayurved had repeatedly violated the 1945 Drugs and Cosmetic Rules.

The 14 drugs that had been suspended were: Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eye Drop.

At the previous hearing on July 9, Patanjali Ayurved told a bench of Justices Hima Kohli and Sandeep Mehta that it had instructed 5,606 franchise stores to withdraw these products.

Media platforms were also instructed to withdraw advertisements for the 14 products, said the company. The court had asked Patanjali Ayurved to file an affidavit within two weeks, stating if social media intermediaries had withdrawn advertisements for the products.

At Tuesday’s hearing, the Indian Medical Association told the court that the 14 products were still available over the counter, even though Patanjali had earlier reportedly stopped their manufacturing.

Patanjali then told the court that the state government cancelled the suspension order on July 1 after considering the report of a committee constituted to look into the matter, reported Live Law.

Related Posts

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid